Mesenchymal stem cells therapy (Therapeutic Solutions International)

StemRIM Inc. has secured European and Chinese patents for its peptide drug Redasemtide, designed to treat various cartilage disorders including osteoarthritis and osteochondritis dissecans.

Brainstorm Cell Therapeutics has received FDA clearance to initiate a Phase 3b trial of NurOwn for the treatment of Amyotrophic Lateral Sclerosis (ALS), marking a significant advancement in their clinical development program.

The Department of Health – Abu Dhabi has completed a groundbreaking Phase I/II clinical trial of StromaForte, a mesenchymal stem cell therapy for knee osteoarthritis, demonstrating a favorable safety profile with no serious adverse events.

BioRestorative Therapies reported a 175% revenue increase to $401,000 in 2024, with a 24% improvement in operating loss and a strong cash position of $10.7 million with no outstanding debt.

Longeveron's Phase 2a CLEAR MIND trial demonstrated that laromestrocel (formerly Lomecel-B) is safe and well-tolerated in patients with mild Alzheimer's disease, with no reported cases of amyloid-related imaging abnormalities.